Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2230 in Healthy Adult Participants
NCT07352423Phase 1Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing Placebo with ALXN2230 (2 arms). Primary endpoint: Number of Participants with Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events at 113 days. Started Mar 2026; status: recruiting.
02
Drugs
ALXN2230
Beyond the preview
Go deeper on NCT07352423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07352423.